Faeth Therapeutics is a clinical-stage biotechnology company developing cancer drugs that simultaneously block multiple nodes of the PAM (PI3K/AKT/mTOR) pathway, one of the most frequently altered routes in tumors. Its pipeline includes programs for endometrial cancer and hormone receptor–positive breast cancer. The approach grew out of research on how tumor cells use nutrients and growth-signaling pathways to survive.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -4.9 | — |
| Q3 2025 | 0 | — | -4.6 | — |
| Q4 2025 | 0 | — | -4.7 | — |
| Q1 2026 | 0 | — | -170.2 | — |
| Q2 2026 | 0 | — | -16 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Chilwa Minerals Limited (CHWM), Aclaris Therapeutics, Inc. (ACRS), NVE Corporation (NVEC), B&R Technology Merger Corp. (BRTM), MasterCraft Boat Holdings, Inc. (MCFT), Aquestive Therapeutics, Inc. (AQST)